Semax

Controlled human evidence.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Semax is a synthetic ACTH-fragment-related peptide studied for neurological effects. Its human literature includes Russian clinical reports in stroke and other settings. Such studies need to be read according to their design and patient population, rather than as proof of general cognitive enhancement. [1]

02 Potential benefits

Studied for neuroprotective and cognitive effects. Has regional medical use and a distinct Russian research history. [1]

03 Evidence & its limits

The cited stroke report does not establish benefit in healthy users or long-term safety. FDA also identifies potential immune reactions from aggregation or peptide impurities and insufficient safety information for compounded Semax. Regional research and online availability do not resolve those gaps. [1]

04 Risks & unknowns

Not FDA-approved. Independent, large, well-controlled human evidence is limited. [1]

05 Status & scope

Not FDA-approved. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] Semax stroke clinical report, 1997
[3] FDA compounding safety concerns

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.